Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Hercules Capital (HTGC) is back in focus after Hunterbrook Capital accused the business development company of exaggerating a key credit performance metric, triggering securities law investigations and fresh questions around its portfolio valuation practices.

See our latest analysis for Hercules Capital.

The latest allegation driven sell off leaves Hercules Capital trading at US$14.51, with a 1 day share price return of 3.2% after a sharp 90 day share price decline of 22.61% and a 1 year total shareholder return of 14.54% in the red. However, the 3 year total shareholder return of 62.52% shows how different the longer view looks compared to recent sentiment around credit quality and valuation questions.

If you are weighing Hercules Capital against other possibilities, this could be a useful moment to look across the market at 20 top founder-led companies

So with Hercules Capital trading at US$14.51 and screens flagging a roughly 40% intrinsic discount, is the current weakness offering you an entry point, or is the market already adjusting for tougher questions on growth and credit quality?

Most Popular Narrative: 28.5% Undervalued

Hercules Capital's most followed narrative pegs fair value at $20.31 versus the last close at $14.51, and the gap hinges on how investors see future earnings resilience in specialty lending.

Recent research on Hercules Capital has focused on fine tuning valuation rather than calling for a major shift in the story. Price targets have been adjusted by US$1, with analysts citing higher modeled discount rates and tweaks to assumed future P/E, while keeping their broader long term outlook largely intact.

Read the complete narrative.

Curious what keeps fair value steady while the share price slides? The narrative leans on earnings, margins and a future multiple that assumes the current growth engine keeps working. The tension is in how far those assumptions can stretch before the valuation story changes.

Result: Fair Value of $20.31 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, tougher competition in venture lending, along with Hercules Capital's heavy tilt to technology and life sciences, could quickly challenge the margin and credit assumptions behind that undervaluation story.

Find out about the key risks to this Hercules Capital narrative.

Next Steps

With sentiment clearly split between concern and optimism, this is a moment to look at the numbers yourself and move quickly to form your own stance using our 4 key rewards and 2 important warning signs